Pharma BD Deal Intelligence
A $300M rare-disease bolt-on that Sigma-Tau flipped one asset from (Oncaspar) for ~$900M five years later — one of the best-aged small pharma carve-outs on record, though the other three legacy products faded.
Full analysis, sources & comparables →Enzon to sell specialty pharma business to Sigma-Tau for $300M cash plus up to $27M milestones plus 5-10% royalties on incremental sales through 2014.
Enzon completed the sale to Sigma-Tau in January 2010, receiving $300M at closing with milestone and royalty upside through 2014.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$300M cash + up to $27M milestones + 5-10% royalties on incremental sales. Oncaspar, Adagen, DepoCyt, Abelcet. Source: Enzon filings, Pharma Times, C&EN.
A $300M rare-disease bolt-on that Sigma-Tau flipped one asset from (Oncaspar) for ~$900M five years later — one of the best-aged small pharma carve-outs on record, though the other three legacy products faded.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sigma-Tau Group / Enzon Pharmaceuticals (Specialty Pharma business) (this deal) | 2009 | $327M | 85 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| QIAGEN N.V. / DxS Ltd. | 2009 | $130M | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
← Browse all deals · How we score deals
More: 2009 deals